Singapore markets open in 6 hours 7 minutes

Biomea Fusion, Inc. (BMEA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.15+0.30 (+6.17%)
As of 02:52PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close4.85
Open4.86
Bid5.15 x 100
Ask5.18 x 100
Day's range4.69 - 5.21
52-week range3.61 - 36.36
Volume941,371
Avg. volume1,276,758
Market cap185.115M
Beta (5Y monthly)-0.37
PE ratio (TTM)N/A
EPS (TTM)-3.55
Earnings date01 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est31.83
  • Simply Wall St.

    Franco Valle Bought 42% More Shares In Biomea Fusion

    Even if it's not a huge purchase, we think it was good to see that Franco Valle, the CFO & Principal Accounting Officer...

  • Insider Monkey

    Biomea Fusion, Inc. (NASDAQ:BMEA) Downgraded by Barclays

    We recently compiled the list of the Analysts on Wall Street Lower Ratings for These 10 Stocks. In this article, we are going to take a look at where Biomea Fusion, Inc. (NASDAQ:BMEA) stands against the other stocks that received a downgrade from Wall Street analysts. But first, we are going to take a look at […]

  • GlobeNewswire

    Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

    REDWOOD CITY, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea’s ongoing Phase I/II clinical trials of the Company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively. The Company will continue ongoing safety and efficac